

09 Jan 2024 | News

Chinese-Language Podcast: AZ MNC 2024

China Cell Therapy M&A, 2024 Outlook

by **Brian Yang**

One week into 2024 and there have already been multiple deals between Chinese innovative drug developers and multinational partners, along with the significant acquisition of GracellBio by AstraZeneca. In this Chinese-language podcast, Brian Yang and Dexter Yan invite a guest speaker to discuss the reasons behind the particularly active China biotech deal-making scene.

Welcome to the Year of the Dragon!

Entering 2024, there have already been multiple recent deals between Chinese innovative drug developers and multinationals, including Medilink and [Roche Holding AG](#), [Harbour BioMed](#)'s Mona and [Seagen Inc.](#) (under [Pfizer Inc.](#)) and [Hansoh Pharmaceutical Group Company Limited](#) with [GlaxoSmithKline Pharmaceuticals Ltd.](#)

Meanwhile, [Novartis AG](#) has announced it is to acquire Singapore-based [SanReno Therapeutics](#), founded just in January 2022 and focusing on kidney diseases.

Apart from antibody-drug conjugates, other modalities have also received attention in recent transactions, and Scrip's Brian Yang and Dexter Yan, along with special guest Liu Liu, formerly of [JW Therapeutics Co., Ltd.](#), look at some of the emerging trends in this Chinese-language podcast. (Also see "[Roche Signs Up Medilink As China Biotech ADC Deal Spree Continues](#)" - Scrip, 4 Jan, 2024.)

The most notable recent China-related biopharma deal of all in recent months is the acquisition of CAR-T-focused [Gracell Biotechnologies Co. Ltd.](#) by [AstraZeneca PLC](#), with the UK firm set to pay

